Search Results 1171-1180 of 17020 for monoclonal antibody
Prior treatment with monoclonal antibodies or any radio- or toxin- immunoconjugates within 3 months of study drug administration. However rituximab treatment ...
Exposure to another investigative drug (small molecules as well as monoclonal antibodies) ... The minimum interval since exposure to any other (non-antibody) ...
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...
Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy. Uncontrolled infectious complications not ...
Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose; Radiation therapy (RT): patients must have had their last fraction of ...
Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before enrollment. Planned administration of growth factors or ...
Learn about this cancer that forms from white blood cells called plasma cells. Treatments include medicines and bone marrow transplant.
... antibody). Signs of active herpes simplex type 1 or 2 or varicella within 4 ... Exposure to monoclonal antibodies, cytokines, growth factors, soluble ...
... monoclonal antibody therapy, amatuximab or any of its excipients); Pregnant and/or lactating females are excluded. A negative beta-human chorionic ...
... monoclonal antibody - Treatment with IV anti-cancer therapy =< 3 weeks prior to registration or with oral anti-cancer therapy =< 1 week prior to ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.